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Abstract  
Aim: To evaluate the influence of periodontal therapy on epigenetic modifications in chronic 
periodontitis patients compared to healthy individuals.  
Methods: Ten patients with healthy periodontium and ten patients with chronic moderate 
periodontitis were enrolled. Gingival biopsies were collected at baseline for both groups and at 2 & 
8 weeks post-periodontal therapy for the disease group (from normal and periodontitis sites). 
Random-intercept linear regression models were applied to evaluate methylation levels across 
groups at baseline and to assess changes in the disease group overtime, separately for normal and 
periodontitis sites.  
Results: Periodontal therapy restored methylation levels of TNF-α, IFN-γ and COX-2 genes in 
periodontitis sites after 2 & 8 weeks to levels reported in normal sites. A DNA methylation gradient 
of COX-2 promoter region was observed at baseline for healthy group and periodontitis group 
(percentage mean in normal sites = 8.8 ± 5.7, p= 0.47 vs healthy; percentage mean in periodontitis 
sites = 13.2 ± 7.3, p = 0.03 vs healthy). Maintenance of high LINE-1 methylation on periodontitis 
sites was observed throughout all data points, suggesting up-regulation of methyltransferase in 
chronic disease. 
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Conclusions: Periodontal therapy resets the DNA methylation of inflammatory genes to levels 
observed in normal sites. Maintenance of high levels of DNA methylation was higher in periodontitis 
sites, reflecting methyl-transferase up-regulation in chronic disease. 
Keywords: Periodontal Diseases/therapy, Epigenetics, DNA Methylation, Inflammatory genes, 
Biomarkers 
 
Abstract  
Obiettivo dello studio: Valutare l’influenza della terapia parodontale sulle modifiche epigenetiche 
in pazienti con parodontite cronica rispetto a pazienti sani. 
Metodi: Sono stati reclutati 10 pazienti parodontalmente sani e 10 affetti da parodontite cronica 
moderata. Lo studio si è articolato raccogliendo campioni di tessuto gengivale in tre momenti: 
baseline (per entrambi i gruppi), 2 settimane dopo la terapia parodontale (solo per il gruppo malato, 
eseguiti due prelievi per paziente: sito sano “SS” e sito malato “SM”), ad 8 settimane (solo per il 
gruppo test, rieseguiti i due prelievi). Sono stati usati “random-intercept linear regression models” 
per valutare le variazioni di metilazione tra gruppi al baseline ed eventuali cambiamenti nel gruppo 
malato, nei siti sia sani che malati, nel corso dello studio. 
Risultati: La terapia parodontale ha riportato, dopo 2 e 8 settimane, i livelli di metilazione dei geni di 
TNF-α, IFN-γ e COX-2 dei SM ai livelli osservati nei SS. 
Per COX-2, al baseline, è stato riscontrato una differenza di metilazione della regione promotrice del 
DNA tra pazienti sani e parodontopatici (percentuale media in SS= 8.8 ± 5.7, p= 0.47 rispetto ai 
pazienti sani. Percentuale media in SM= 13.2 ± 7.3, p = 0.03 rispetto ai pazienti sani). 
Inoltre, nei siti con parodontite, è sempre risultato, un alto livello di metilazione di LINE-1, indice di 
iperespressione dell’enzima DNA metil-transferasi che si verifica in caso di malattia cronica. 
Conclusioni: La terapia parodontale è in grado di riportare i livelli di metilazione dei geni analizzati 
nei SM ai livelli dei SS. Inoltre, l’ipermetilazione del genoma dei SM riflette l’upregulation 
dell’enzima DNAmetil-transferasi tipico della malattia cronica. 
Keywords: Periodontal Diseases/therapy, Epigenetics, DNA Methylation, Inflammatory genes, 
Biomarkers 
 
Introduction  
Periodontitis is a multifactorial disease caused predominantly by gram-negative, anaerobic and 
microaerophilic bacteria that can colonize the subgingival regions (Page, 1991; Page & Kornman, 
1997), and eventually trigger an inflammatory host response influenced by environmental, genetic 
and epigenetic factors (Borrell & Papapanou, 2005; Takashiba & Naruishi, 2006; Kornman, 2008). 
Of interest to this study, epigenetic modification can further regulate gene expression of an 
individual’s immune response (Schulz et al, 2016), and despite the well-established influence of 
epigenetic modification in cancer and inflammatory diseases (Fitzpatrick & Wilson, 2003; Adcock et 
al, 2007; El Gazzar et al, 2007; Ngollo et al, 2014), little is known in the context of oral health (Lod 
et al, 2014).  
In general, epigenetics embodies the modifications of gene expression, without changing the DNA 
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sequence, (Bird, 2002; Adcock et al, 2007) through chemical alterations of DNA and associated 
proteins (Barros & Offenbacher, 2014) that evoke chromatin remodeling and a successive rapid 
inactivation (turn off) or activation (turn on) of genes (Larsson et al, 2015). Notably, such alterations 
occur through two major mechanisms in human cells (Shaw, 2006); DNA methylation and histone 
modifications (Wilson, 2008) that are reversible (Lod et al, 2014), and linked (Jenuwein & Allis, 
2001; Robertson & Wolffe, 2000). Nevertheless, DNA methylation offers a more stable form of 
gene regulation (Bäckdahl et al, 2009) characterized by the addition of a methyl group, through 
DNA methyl-transferase enzymes, to the fifth carbon on the cytosine base within CpG islands, which 
are frequently found in the promoter region of the gene (Sanders, 2006), consequently inhibiting 
gene expression.  
Accordingly, most of the studies exploring the link between epigenetics and periodontal disease 
have investigated the changes in the DNA methylation of genes (Baptista et al, 2014; Andia et al., 
2015), involved in the regulation of cytokine production, since these signaling molecules play a key 
role in periodontal tissue breakdown; for reviews: see (Barros & Offenbacher, 2014; Lod et al, 
2014; Larsson et al, 2015). Emerging studies are also demonstrating the activation of inflammatory 
pathways like the NFkB signaling pathway by histone modifications  (Martins et al, 2016).  
Various studies demonstrated a lower level of DNA methylation of genes expressing pro-
inflammatory cytokines in periodontitis patients, either chronic or aggressive, compared to those 
with a healthy periodontium, leading to over-expression of these mediators in inflamed tissues 
(Oliveira et al, 2009; Andia et al, 2010; Zhang et al, 2010a; Ishida et al, 2012). Nevertheless, 
hypermethylation has been interestingly described for certain genes in the chronic state of 
periodontal disease, as a down-regulatory mechanism to prevent unrestricted tissue destruction 
(Zhang et al, 2010b). 
Although several epigenetic alterations have been described in periodontal disease, little is known 
about the efficacy of periodontal therapy in reestablishing normal DNA methylation levels in 
patients. The prospective positive effects of periodontal therapy on the methylation profile of DNA 
and specific genes came from the study of Andia & colleagues (2015) that found no changes 
between healthy tissues and periodontitis after a three months follow-up. These findings suggest 
that periodontal therapy can influence epigenetic modifications. However, variations in the 
methylation level between both groups were not assessed at baseline (before therapy), and 
samples of inflamed tissues were not investigated.  
Based on these observations, we conducted a clinical study to monitor the changes in DNA 
methylation of LINE-1, TNF-α, IFN-J and COX-2 inflammatory genes in periodontitis patients 
following periodontal therapy in comparison to disease free subjects at both the site and patient 
levels. 
 
Materials and Methods  
This study was approved by the ethical committee of the University of Milan, Italy and was 
conducted in the period between October 2015 and June 2016. 
- Study Participants & Inclusion Criteria:  
From the pool of patients attending a private dental practice in Piacenza- Italy, twenty individuals 
were enrolled equally in two groups: “disease free” including ten patients with healthy 
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periodontium and a “periodontal disease group” including ten chronic moderate periodontitis 
patients. All participants were voluntarily included in the study after explaining its objectives and 
obtaining their verbal and written informed consent.  
Study participants fit the following inclusion criteria:  
1. Patients older than 18 years of age.  
2.  Patients without any systemic diseases.   
3. Non-smokers. 
4. Patients of the same Caucasian origin (Italian descent).  
5. For the disease free group: patients who showed no clinical signs of gingival inflammation and 
had no history of periodontitis were included.  
6. For the periodontal disease group: patients diagnosed with chronic periodontitis, based on the 
American Academy of Periodontology (AAP) Workshop (Armitage, 1999) were included. 
Patients in this group must have had at least a normal site (PD < 4 mm with no signs of 
bleeding on probing, mobility and inflammation) and a periodontitis site (PD ≥ 5 mm) for 
later biopsy harvesting.  
The exclusion criteria were the following:  
1. Current pregnancy 
2. Patients who reported the use of antibiotics and/or non-steroidal anti-inflammatory drugs 
(NSAIDs), for at least one month before enrolment in the study.  
- Study timeline & Periodontal Parameters:  
* Baseline: For all study participants, probing pocket depth (PPD), clinical attachment level (CAL), 
bleeding on probing (BOP), full mouth plaque score (FMPS) and full mouth bleeding score (FMBS) 
were recorded at six sites around each tooth. Next, gingival biopsies, using a 3 mm of diameter 
punch, were obtained from the disease free group during crown lengthening procedures or 
surgical removal of wisdom teeth. In the periodontal disease group, biopsies were harvested from 
two sites: a normal site and a periodontitis site with a purpose to compare methylation levels 
between both. Following biopsy collection, chronic periodontitis patients underwent conventional 
periodontal therapy; full mouth scaling and root planing with ultrasonic and manual instruments. 
Chlorhexidine mouthwash (0.2%) was prescribed for daily use (twice a day for twenty days).  
* Two weeks after periodontal therapy: PPD, CAL & BOP, FMPS & FMBS were registered and 
gingival biopsies were harvested for the disease group only, from a normal and periodontitis site, 
to analyze the influence of periodontal therapy on epigenetic modifications, in comparison to 
baseline. 
* Eight weeks after periodontal therapy: As at the 2 weeks time point, PPD, CAL, BOP, FMPS & 
FMBS were registered and gingival biopsies were harvested for the disease group only (from two 
sites), to analyze the influence of periodontal therapy on epigenetic changes, in comparison to 
those observed among disease free and periodontal disease groups at baseline and in the 
periodontal disease group at 2 weeks. 
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- Sample Collection, DNA Extraction, and Bisulfite Treatment:   
Briefly, freshly harvested tissues were collected in vials and submerged in Allprotect Tissue Reagent 
(Qiagen, USA) to stabilize DNA immediately, and were stored at 2-8 °C for up to 6 months. DNA was 
extracted using the QIAamp DNA Mini Kit (Qiagen) following the manufacturer’s recommendations. 
EZ DNA Methylation-Gold™ Kit (Zymo Research, Orange, CA, USA) was used to treat 500 ng DNA 
(concentration 25 ng/µl) according to the manufacturer’s protocol. Bisulfite-treated DNA was eluted 
in 300 µl of M-Elution Buffer. 
- Analysis of DNA Methylation:  
Analysis of DNA methylation was performed using previously published methods, (Bollati et al. 
2007; Tarantini et al. 2013) with minor modifications. Briefly, a 50 µl PCR was carried out in 25 µl of 
GoTaq Hot Start Green Master Mix (Promega, Madison, WI, USA), 1 pmol of the forward primer, 1 
pmol of the biotinylated reverse primer, 25 ng of bisulfite-treated genomic DNA and water. Primers 
for DNA methylation analysis and PCR cycling conditions are shown in table 1.  
The biotin-labeled primers were used to purify the final PCR product using Sepharose beads.  The 
PCR product was bound to Streptavidin Sepharose HP (Amersham Biosciences, Uppsala, Sweden) 
and the Sepharose beads containing the immobilized PCR product were purified, washed, 
denatured using a 0.2 M NaOH solution, and washed again using the Pyrosequencing Vacuum Prep 
Tool (Pyrosequencing, Inc., Westborough, MA), as recommended by the manufacturer. Then, 0.3 µl 
Pyrosequencing primer was annealed to the purified single-stranded PCR product, and 
Pyrosequencing was performed using the PyroMark MD System (Pyrosequencing, Inc.). The degree 
of methylation was expressed as a percentage of methylated cytosines divided by the sum of 
methylated and unmethylated cytosines (%5mC).  
- Statistical Analysis:  
In order to take into account correlations within subjects, random-intercept linear regression 
models were applied to evaluate methylation levels across groups at baseline and to evaluate 
methylation changes over time in the periodontal disease group, separately for the normal and 
periodontitis sites. Statistical analyses were performed with Stata 13 (StataCorp. 2013) (Rabe-
Hesketh et al, 2008). 
 
Results 
Twenty participants (8 males, 12 females) were included in this study, distributed into “disease 
free” (7 males, 3 females) and “periodontal disease” groups (3 males, 7 females). The age in the 
disease free group was between 25 and 69 years old (mean = 53.3 ± 12.3 years), while the range 
was 26-60 years old in the periodontal disease group (mean = 46.6 ± 10 years). Nineteen 
participants completed the study, as demonstrated in the CONSORT flow diagram (figure 1).  
Success of periodontal therapy. We only reported the improvement of periodontal pocket depth in 
the disease group overtime, because this parameter provides an assessment of disease presence in 
respect to attachment loss/bone loss measurements which reflect past experience of periodontitis 
(Tonetti & Claffey, 2005). Periodontal therapy in the periodontal disease group was successful 
based on the changes in the mean of PPD over time. Mean PPD at baseline was 4.2 ± 0.4 mm 
indicating a moderate periodontal disease. After treatment mean PPD was 2.9 ± 0.4 mm (p < 0.001) 
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at 2 weeks and 2.5 ± 0.3 (p < 0.001) at 8 weeks. In the disease free group PPD at baseline in all sites 
was ≤ 3mm. Demographic and clinical characteristics of the study sample are shown in table (2).  
Periodontal disease patients present reduced methylation of TNF-α in normal and diseased sites 
compared with healthy population. The promoter region was more methylated in disease free 
individuals (36.6% ± 9.2), compared to normal & periodontitis sites of the periodontal disease group 
(34.1% ± 5.2 and 31.4% ± 7.8 respectively), indicating a relatively more active gene expression of 
TNF-α in the state of disease. Methylation status remained almost stable in normal sites throughout 
the evaluation period. In the periodontitis sites, however, methylation level was almost stable up to 
2 weeks. Afterward, it started to rise reaching 33.7% ± 7.4 at 8 weeks, which is quite close to that 
reported in normal sites at baseline. Nonetheless, these results were not statistically significant (P 
value > 0.05), neither among groups nor among sites.  
IFN-J present increased methylation within periodontitis tissues. The promoter region of IFN-J 
gene was “hypermethylated” among all entities, with the disease free group displaying the highest 
methylation percentage among all (88.6% ± 1.4) reflecting a decreased gene expression of IFN-γ in 
the state of periodontal health. Regarding the periodontal disease group, the level of methylation in 
periodontitis sites was almost comparable to disease free individuals (88.3% ± 2.1), while normal 
sites exhibited a slightly lower methylation (85.8% ± 6.5), implying a down-regulatory mechanism in 
periodontitis sites to cease further destruction of periodontal tissues. Through time, DNA 
methylation in periodontitis sites started to decline, reaching at 8 weeks a percentage almost 
equivalent to that reported in normal sites at baseline (86.2% ± 3.8). On the other hand, 
methylation levels started to increase in normal sites, approaching a level at 8 weeks a comparable 
to the disease free group (88.8% ± 2.8). None of these findings was statistically significant (P value > 
0.05).  
Periodontal therapy reduces the methylation of COX-2 promoter. Unlike TNF-J and IFN-J, COX-2 
promoter region was highly “hypomethylated” in periodontium of disease free patients (6.7% ± 7.6). 
DNA methylation was nearly as twice as high in the periodontitis sites (13.2% ± 7.3), while on 
normal tissues from periodontal disease patients it was 8.8% ± 5.7. High levels of COX-2 methylation 
in periodontitis sites can render an intrinsic protective mechanism capable of preventing the 
unrestrained breakdown of the periodontium. Such discrepancies in the mean of methylation 
between normal and periodontitis sites in comparison to free disease group at baseline were 
statistically significant (P=0.47 for normal sites vs disease free group, P=0.03 for periodontitis sites 
vs disease free group). Following periodontal treatment, methylation percentage decreased 
dramatically in periodontitis sites, at 2 weeks, almost to half (5.8% ± 3.2, P <0.001 vs baseline), with 
a very slight rise from 2 weeks to 8 weeks (7.2% ± 4.3, P=0.004 vs baseline), which is still higher than 
the methylation level reported in the disease free group. On the contrary, the mean percentage of 
methylation steadily declined in normal sites, reaching 5% ± 1.9 at 8 weeks, P=0.03 vs baseline).  
High levels of COX-2 methylation at baseline in the periodontal disease group can render an intrinsic 
protective mechanism capable of preventing the unrestrained breakdown of the periodontium 
LINE-1 promoter methylation in periodontal disease. To evaluate the DNA methylation at a 
broader level, we explored the methylation profile of LINE-1 promoter region. We observed that the 
mean percentage of methylation was similar between the disease free group (69.5% ± 3.5) and 
normal sites in diseased patients (69.4% ± 2.1), and remained fairly stable during the observation 
period. Nevertheless, periodontitis sites underwent increased methylation of the promoter region 
(70.2% ± 2.8), showing an increase in the methylation percentage at 8 weeks (71.7% ± 2.8). The 
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variations in the methylation profile between different entities were not statistically significant (P 
value > 0.05). 
Mean methylation percentages of the selected genes and p values are summarized in table 3. DNA 
methylation patterns for each gene among different groups and in different points of time are 
demonstrated in figure 2.  
 
Conclusions  
Here we provide for the first time evidence of epigenetic modifications mediated by periodontal 
therapy. Due to the well-established association of methylation with stable gene regulation, we 
chose to evaluate the status of DNA methylation instead of the acetylation of genes related to 
inflammation (Bäckdahl et al, 2009).  
Our study presents the expression pattern of methylated genes before periodontal therapy and 
during the two months follow-up. Since alterations in the methylation patterns might vary from site 
to site within the same individual (Barros & Offenbacher, 2014), we assessed the epigenetic 
modifications in normal and periodontitis sites within the same chronic periodontitis patient. We 
also compared our data to tissue samples from healthy periodontium. Our study gave emphasis to 
the methylation status of the tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), and 
the cyclooxygenase-2, (COX-2, also known as prostaglandin-endoperoxide synthase 2 or PTGS2) as 
key genes associated with periodontal disease progression. We also carefully selected the long 
interspersed nuclear element-1 (LINE-1) gene as a genome-wide readout for methylation. Of note, 
our cohort of patients includes Caucasians of Italian descent, and careful interpretation of the 
results must take into consideration the potential ethnicity influence over epigenetic modifications 
(Kwabi-Addo et al, 2010; Straughen et al, 2015).  
Based on the findings of the present study, we can conclude that; (i) periodontal treatment does 
influence the DNA methylation pattern of various inflammatory genes, (ii) in periodontitis sites, the 
promoter region of different inflammatory genes was either hypo- or hypermethylated, depending 
on the activation of a down-regulatory mechanism to limit ongoing destruction of periodontal 
tissues, (iii) periodontal therapy is not sufficient to reset the methylation levels of inflammatory 
genes in periodontitis sites to health levels of periodontitis-free patients, at least on the short term. 
However, DNA methylation in periodontitis sites was restored to that of normal sites. (iv) The 
methylation profile from normal tissues was either restored or not to healthy patient levels, 
depending on the inflammatory gene, which suggests that unaffected sites from periodontal 
disease patients are more prone to periodontal tissue breakdown with the presence of other factors 
and thus should frequently be monitored within a tailored maintenance phase of periodontal 
therapy. In fact, such information might help to better elucidate disease development in healthy 
sites in susceptible periodontitis patients, which needs to be further investigated for implementing 
appropriate intervention plans (Mdala et al, 2014). 
On a global methylation perspective, periodontally-diseased sites showed a different DNA 
methylation profile in comparison to normal sites and disease free patients, even after periodontal 
treatment. These findings suggest that the local effects of the disease have an influence on the 
epigenetics of the tissues that may be modulated by environmental factors, including the 
microbiota. In this context, future investigations should further explore the identification of specific 
factors that affect the local epigenetics of periodontal soft and hard tissues. 
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Despite these findings, the results of the study must be interpreted with caution as it has certain 
limitations. Gingival biopsies of normal and inflamed tissues were harvested from different sites and 
not the same one during different points of time. Sample collection from the same site is preferable 
when evaluating the influence of periodontal therapy over time, however, that wasn’t possible 
because 2 weeks after periodontal therapy soft tissues at the biopsy site were not completely 
healed. Also, findings of this study represent data on the short-term. Thus, epigenetic changes still 
need to be monitored on the long-term to understand if the methylation status in chronic 
periodontitis could turn out similar to that in healthy individuals with no history of periodontitis, 
following an effective periodontal therapy, maintenance, and compliance.  
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Table 1. Primers Used for DNA methylation analysis and PCR cycling conditions  
Sequence ID 
Forward Primer 
(5’ to 3’) 
Reverse Primer 
(5’ to 3’) 
Sequencing Primer 
(5’ to 3’) 
Sequence 
analyzed* 
(5’ to 3’) 
Annealing 
conditions 
Fragment 
size (bp)  
Chr and CpG 
positions 
Repetitive element methylation analysis   
LINE-1 TTTTGAGTTAGGTGTGGGATATA 
Biotin-
AAAATCAAAAAATTCC
CTTTC 
AGTTAGGTGTGGGAT
ATAGT 
TTC/TGTGGTGC/T
GTC/TG 50°C for 30 seconds 146 
 
Gene-specific methylation analysis  
COX-2 GGAGATTAGTTTAGAATTGGTTTT 
Biotin-
AATCCCCACTCTC
CTATCTAATCC 
AAGAAGAAAAGATA
TTTGG 
C/TGGAAATTTGTG
C/TGTTTGGGGC/T
GGTGGAATTC/TG
GGG 
59°C for 60 seconds 139 
Chr1 
Pos1: 186649540 
Pos2: 186649552 
Pos3: 186649561 
Pos4: 186649570 
IFN-γ 
Biotin-
GTTTTTTGGATTTGATTAGTTT
GA 
CAATAACAACCA
AAAAAACCCA 
TATAACTTATATATTT
CATC 
G/ATTTCCG/AAAA
AAATTAAACC 54°C for 60 seconds 143 
Chr12 
Pos1: 66840192  
Pos2: 66840186  
TNF-α 
Biotin-
TGAGGGGTATTTTTGATGTTTG
T 
CCAACAACTACCT
TTATATATCCC 
ATAAACCCTACACCT
TCTAT- 
CTCA/GATTTCTTC
TCCATCA/GCA/GA
AAACA/GAAAA 
57°C for 60 seconds 208 
Chr 6 
Pos1:31651172; 
Pos2:31651157; 
Pos3:31651155; 
Pos4: 31651149 
* Nucleotides at which DNA methylation was measured are underlined 
* Chr = Chromosome, Pos= Position  
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Table 2. Demographic and clinical characteristics of the study sample 
 
Demographic/Clinical 
characteristics 
Disease 
Free Group 
(n =10) 
Periodontal Disease Group (n =10) 
Males/Females 7/3 3/7 
Age (years) 
(Mean ± SD) 
53.3 ± 12.3 46.6 ± 10.0 
Probing Depth (mm) 
(Mean ± SD) 
At baseline At baseline Two weeks 
after 
periodontal 
treatment 
Eight weeks 
after 
periodontal 
treatment 
 ≤ 3 4.2 ± 0.4 2.9 ± 0.4 2.5 ± 0.4 
  Reference P <0.001 P <0.001 
 
*P-values from random intercept linear regression model. 
  
 
Table 3. Methylation of selected genes across groups and over time. Results of random-intercept 
linear regression models 
  Methylation 
percentage 
(Mean ± SD) 
  
Genes Group At baseline Two weeks after 
periodontal treatment 
Eight weeks after 
Periodontal treatment 
TNF-α Disease Free  36.6 ± 9.2 - - 
 Periodontal 
Disease/Normal 
Sites  
34.1 ± 5.2  33.9 ± 6.5  34.0 ± 9.3 
  P=0.44 vs Disease 
free 
P=0.92 vs baseline P=0.90 vs baseline 
 Periodontal 
Disease/ 
Periodontitis Sites 
31.4 ± 7.8  31.5 ± 8.5  33.7 ± 7.4 
  P=0.11 vs Disease 
free 
P=0.97 vs baseline P=0.50 vs baseline 
     
IFN-γ Disease Free 88.6  ± 1.4 - - 
 Periodontal 
Disease/Normal 
Sites  
85.8  ± 6.5 87.7 ± 3.5 88.8 ± 2.8 
  P=0.10 vs Disease 
free 
P=0.33 vs baseline P=0.14 vs baseline 
 Periodontal 
Disease/ 
Periodontitis Sites 
88.3  ± 2.1 88.4 ± 2.2 86.2 ± 3.8 
  P=0.85 vs Disease 
free 
P=0.89 vs baseline P=0.08 vs baseline 
     
COX-2 Disease Free 6.7  ± 7.6 - - 
 Periodontal 
Disease/Normal 
Sites  
8.8  ± 5.7 6.6 ± 3.6  5.0 ± 1.9 
  P=0.47 vs Disease 
free 
P=0.18 vs baseline P =0.03 vs baseline 
 Periodontal 
Disease/ 
Periodontitis Sites 
13.2  ± 7.3 5.8 ± 3.2 7.2 ± 4.3 
  
  
   P =0.03 vs Disease 
free 
P <0.001 vs baseline P=0.004 vs baseline 
     
LINE-1 Disease Free  69.5 ± 3.5 - - 
 Periodontal 
Disease/ Normal 
Sites  
69.4 ± 2.1 70.0  ± 2.3 69.5 ± 1.4 
  P=0.92 vs Disease 
free 
P=0.36 vs baseline P=0.91 vs baseline 
 Periodontal 
Disease/ 
Periodontitis Sites 
70.2 ± 2.8 70.7 ± 2.8 71.7 ± 2.8  
  P=0.58 vs Disease 
free 
P=0.61 vs baseline P=0.22 vs baseline 
*P-values calculated with random-intercept linear regression models. 
 
                 
  
  
  
Figure 1. CONSORT Flow Diagram of the Study Sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Disease free 
group (n = 10) 
 
 
Dropout 
on the 8th 
week 
(n=1) 
Chronic 
Moderate 
Periodontitis 
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19 Patients completed the study  
 
- Clinical parameters were 
registered at baseline 
 
- Gingival biopsies were 
obtained only at baseline 
during crown lengthening 
procedures or surgical 
removal of wisdom teeth 
- Clinical parameters were 
registered at baseline, then 2 
weeks and 8 weeks post-
periodontal therapy 
 
- Gingival biopsies were 
harvested from two sites at 
all points of time: a normal 
site and a periodontitis site  
Total number of eligible patients   
(n =20) 
  
 
Figure 2. DNA methylation patterns among different groups and at different points of time, for 
TNF-α, IFN- γ, COX-2 and LINE-1 
 
 
        Circle: Disease-free group 
        Dashed line: Periodontal disease group, normal sites 
        Continuous line: Periodontal disease group, periodontitis sites 
 
 
 
 
 
